These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data. Durie BGM; Kumar SK; Ammann EM; Fu AZ; Kaila S; Lam A; Usmani SZ; Facon T Adv Ther; 2024 May; 41(5):1923-1937. PubMed ID: 38494542 [TBL] [Abstract][Full Text] [Related]
44. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. Takakuwa T; Yamamura R; Ohta K; Kaneko H; Imada K; Nakaya A; Fuchida SI; Shibayama H; Matsuda M; Shimazu Y; Adachi Y; Kosugi S; Uchiyama H; Tanaka H; Hanamoto H; Shimura Y; Kanda J; Onda Y; Uoshima N; Yagi H; Yoshihara S; Hino M; Shimazaki C; Takaori-Kondo A; Kuroda J; Matsumura I; Kanakura Y; Nomura S Eur J Haematol; 2021 Apr; 106(4):555-562. PubMed ID: 33476404 [TBL] [Abstract][Full Text] [Related]
45. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Patel KK; Shah JJ; Feng L; Lee HC; Manasanch EM; Olsem J; Morphey A; Huo XJ; Thomas SK; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ Clin Cancer Res; 2022 Apr; 28(7):1277-1284. PubMed ID: 34992070 [TBL] [Abstract][Full Text] [Related]
46. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323 [TBL] [Abstract][Full Text] [Related]
47. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Kumar SK; LaPlant BR; Reeder CB; Roy V; Halvorson AE; Buadi F; Gertz MA; Bergsagel PL; Dispenzieri A; Thompson MA; Crawley J; Kapoor P; Mikhael J; Stewart K; Hayman SR; Hwa YL; Gonsalves W; Witzig TE; Ailawadhi S; Dingli D; Go RS; Lin Y; Rivera CE; Rajkumar SV; Lacy MQ Blood; 2016 Nov; 128(20):2415-2422. PubMed ID: 27702799 [TBL] [Abstract][Full Text] [Related]
48. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Horigome Y; Iino M; Harazaki Y; Kobayashi T; Handa H; Hiramatsu Y; Kuroi T; Tanimoto K; Matsue K; Abe M; Ishida T; Ito S; Iwasaki H; Kuroda J; Shibayama H; Sunami K; Takamatsu H; Tamura H; Hayashi T; Akagi K; Maeda T; Yoshida T; Mori I; Shinozaki T; Iida S Ann Hematol; 2024 Feb; 103(2):475-488. PubMed ID: 37695378 [TBL] [Abstract][Full Text] [Related]
49. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma. Ohashi Y; Yatabe M; Niijima D; Tani K; Ogawa C; Yachi Y; Kagoo T; Boku S; Ueno H; Yano T; Higai K; Yokoyama A In Vivo; 2020; 34(5):2821-2828. PubMed ID: 32871820 [TBL] [Abstract][Full Text] [Related]
50. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. Iida S; Izumi T; Komeno T; Terui Y; Chou T; Ikeda T; Berg D; Fukunaga S; Sugiura K; Sasaki M Int J Clin Oncol; 2022 Jan; 27(1):224-233. PubMed ID: 34599726 [TBL] [Abstract][Full Text] [Related]
51. Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. Bringhen S; Pour L; Benjamin R; Grosicki S; Min CK; C de Farias DL; Vorog A; Labotka RJ; Wang B; Cherepanov D; Cain LE; Manne S; Rajkumar SV; Dimopoulos MA Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):491-504. PubMed ID: 37149398 [TBL] [Abstract][Full Text] [Related]
52. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data. Ailawadhi S; Cheng M; Cherepanov D; DerSarkissian M; Stull DM; Hilts A; Chun J; Duh MS; Sanchez L Curr Probl Cancer; 2024 Jun; 50():101078. PubMed ID: 38547609 [TBL] [Abstract][Full Text] [Related]
53. Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients. Takezako N; Kosugi H; Matsumoto M; Iida S; Ishikawa T; Kondo Y; Ando K; Miki H; Matsumura I; Sunami K; Teshima T; Iwasaki H; Onishi Y; Kizaki M; Izutsu K; Maruyama D; Tobinai K; Ghori R; Farooqui M; Liao J; Marinello P; Matsuda K; Koh Y; Shimamoto T; Suzuki K Int J Hematol; 2020 Nov; 112(5):640-649. PubMed ID: 32949374 [TBL] [Abstract][Full Text] [Related]
54. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G; Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427 [TBL] [Abstract][Full Text] [Related]
55. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533 [TBL] [Abstract][Full Text] [Related]
56. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221 [TBL] [Abstract][Full Text] [Related]
57. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891 [TBL] [Abstract][Full Text] [Related]
58. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. Ludwig H; Poenisch W; Knop S; Egle A; Schreder M; Lechner D; Hajek R; Gunsilius E; Krenosz KJ; Petzer A; Weisel K; Niederwieser D; Einsele H; Willenbacher W; Melchardt T; Greil R; Zojer N Br J Cancer; 2019 Oct; 121(9):751-757. PubMed ID: 31558804 [TBL] [Abstract][Full Text] [Related]